Suppr超能文献

[戈谢病的诊断与治疗。2000年德国治疗中心的当前建议]

[Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000].

作者信息

Niederau C, Rolfs A, vom Dahl S, Häussinger D, Poll L W, Mengel E, Beck M

机构信息

Klinik für Innere Medizin, St.-Josef-Hospital Oberhausen, Akademisches Lehrkrankenhaus, Universität Essen.

出版信息

Med Klin (Munich). 2001 Jan 15;96(1):32-9. doi: 10.1007/pl00002150.

Abstract

BACKGROUND

Gaucher's disease is the autosomally recessively inherited deficiency of the lysosomal enzyme glucocerebrosidase. Increasing storage of glucocerebrosides leads to a multisystem disease, the prevalence of which is about 1:40,000 in central Europe and up to 1:2,000 in some other countries (e.g. Israel). The acute and chronic neuronopathic forms of the disease (formerly defined as Gaucher types 2 and 3) account for only 5 to 10% of all Gaucher patients in Central Europe and Germany and are thus less frequent than the non-neuronopathic disease (formerly defined as Gaucher type 1). Gaucher's disease is usually associated with spleno- and hepatomegaly, fatigue, skeletal complications, and several corresponding hematological and laboratory abnormalities. In 5 to 10% of the patients there are also central nervous symptoms such as myoclonic seizures, oculomotoric apraxia and a slight mental retardation.

METHODS

Four specialized centers care for more than 2/3 of all German Gaucher patients today. These centers present their consensus recommendations for state-of-the-art diagnosis and treatment of Gaucher's disease.

RESULTS

Recent epidemiological data indicate that only 10 to 20% of all Gaucher patients are correctly diagnosed (and treated) in Germany. The diagnosis today can be done in all patients by noninvasive methods, i.e. determination of the glucocerebrosidase activity in peripheral leukocytes and of the genetic defect. The current enzyme replacement therapy with glucocerebrosidase has proven effective to improve and often normalize hematological abnormalities, hepatosplenomegaly, skeletal complications and quality of life, provided that the therapy is started early and is given at adequate dosages.

CONCLUSION

In view of the availability of an effective therapy, efforts should be made to increase the awareness of Gaucher's disease in differential diagnosis, to help to diagnose the disease with noninvasive techniques at early stages, and to provide practical guidelines for adequate treatment.

摘要

背景

戈谢病是一种常染色体隐性遗传的溶酶体酶葡糖脑苷脂酶缺乏症。葡糖脑苷脂储存增加导致多系统疾病,在中欧其患病率约为1:40000,在其他一些国家(如以色列)高达1:2000。该疾病的急性和慢性神经病变型(以前定义为戈谢2型和3型)在中欧和德国仅占所有戈谢病患者的5%至10%,因此不如非神经病变型疾病(以前定义为戈谢1型)常见。戈谢病通常伴有脾肿大和肝肿大、疲劳、骨骼并发症以及一些相应的血液学和实验室异常。5%至10%的患者还会出现中枢神经症状,如肌阵挛性癫痫、眼球运动失用症和轻度智力迟钝。

方法

如今,四个专业中心照料着德国超过三分之二的戈谢病患者。这些中心提出了关于戈谢病最新诊断和治疗的共识性建议。

结果

最新的流行病学数据表明,在德国,所有戈谢病患者中只有10%至20%得到了正确诊断(并接受了治疗)。如今,所有患者都可以通过非侵入性方法进行诊断,即测定外周血白细胞中的葡糖脑苷脂酶活性和基因缺陷。目前使用葡糖脑苷脂酶的酶替代疗法已被证明有效,可改善并常常使血液学异常、肝脾肿大、骨骼并发症和生活质量恢复正常,前提是治疗开始得早且剂量充足。

结论

鉴于有效治疗方法的可得性,应努力提高对戈谢病在鉴别诊断中的认识,帮助在早期阶段用非侵入性技术诊断该疾病,并提供适当治疗的实用指南。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验